Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 9/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776158 | 1.00 | PREP (0.44) | PREPF2PRSS1PSMB5CXCR2 | |
| SCHEMBL30321063 | 1.00 | PREP (0.44) | PREPF2PRSS1PSMB5CXCR2 | |
| SCHEMBL13067993 | 0.83 | SLC7A5 (0.34) | F2PRSS1 | |
| SCHEMBL13061977 | 0.82 | PSMB5 (0.46) | PREPF2PRSS1PSMB5PSEN1 | |
| SCHEMBL3658623 | 0.82 | PSMB5 (0.46) | PREPF2PRSS1PSMB5PSEN1 | |
| SCHEMBL21365255 | 0.79 | PSMB5 (0.55) | F2PRSS1PSMB5PSEN1PSEN2 | |
| SCHEMBL23656992 | 0.78 | PSMB5 (0.52) | F2PRSS1PSMB5PSEN1PSEN2 | |
| SCHEMBL21365291 | 0.78 | PSMB5 (0.52) | F2PRSS1PSMB5PSEN1PSEN2 | |
| SCHEMBL2772055 | 0.78 | PREP (0.44) | PREPF2PRSS1PSMB5CXCR2 | |
| SCHEMBL19853086 | 0.78 | PREP (0.44) | PREPF2PRSS1PSMB5CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PREP 209/4885F2 2849/4885PRSS1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.